Ww. Roberts et al., Contemporary identification of patients at high risk of early prostate cancer recurrence after radical retropubic prostatectomy, UROLOGY, 57(6), 2001, pp. 1033-1037
Objectives, To develop a model that will identify a contemporary cohort of
patients at high risk of early prostate cancer recurrence (greater than 50%
at 36 months) after radical retropubic prostatectomy for clinically locali
zed disease, Data from this model will provide important information for pa
tient selection and the design of prospective randomized trials of adjuvant
therapies.
Methods. Proportional hazards regression analysis was applied to two patien
t cohorts to develop and cross-validate a multifactorial predictive model t
o identify men with the highest risk of early prostate cancer recurrence. T
he model and validation cohorts contained 904 and 901 men, respectively, wh
o underwent radical retropubic prostatectomy at Johns Hopkins Hospital. Thi
s model was then externally validated using a cohort of patients from the M
ayo Clinic.
Results. A model for weighted risk of recurrence was developed: R-w' = lymp
h node involvement (0/1) x 1.43 + surgical margin status (0/1) x 1.15 + mod
ified Gleason score (0 to 4) x 0.71 + seminal vesicle involvement (0/1) x 0
.51. Men with an R-w' greater than 2.84 (9%) demonstrated a 50% biochemical
recurrence rate (prostrate-specific antigen level greater than 0.2 ng/mL)
at 3 years and thus were placed in the high-risk group. Kaplan-Meier analys
es of biochemical recurrence-free survival demonstrated rapid deviation of
the curves based on the R-w'. This model was cross-validated in the second
group of patients and performed with similar results. Furthermore, similar
trends were apparent when the model was externally validated on patients tr
eated at the Mayo Clinic.
Conclusions, We have developed a multivariate Cox proportional hazards mode
l that successfully stratifies patients on the basis of their risk of early
prostate cancer recurrence. UROLOGY 57: 1033-1037, 2001. (C) 2001, Elsevie
r Science Inc.